Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Or Refractory Non-Hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02340936
What this trial is testing

Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 53
Early research (Phase 1)Ended earlyNCT00005787
What this trial is testing

Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
LymphomaNeutropenia
Northwestern University 3
Early research (Phase 1)Study completedNCT01606878
What this trial is testing

Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Who this might be right for
Childhood Solid NeoplasmRecurrent Childhood Anaplastic Large Cell LymphomaRecurrent Neuroblastoma
Children's Oncology Group 46
Very early researchEnded earlyNCT01878708
What this trial is testing

A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

Who this might be right for
T-Cell LymphomaRelapsed T-Cell LymphomaRefractory T-Cell Lymphoma
Dana-Farber Cancer Institute 2
Testing effectiveness (Phase 2)Looking for participantsNCT04792489
What this trial is testing

DALY II USA/ MB-CART2019.1 for DLBCL

Who this might be right for
Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B Cell LymphomaHigh Grade B-cell Lymphoma (HGBCL)+6 more
Miltenyi Biomedicine GmbH 315
Not applicableApproved For MarketingNCT05733650
What this trial is testing

Expanded Access Program for Epcoritamab

Who this might be right for
Large B-cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-cell Lymphoma (PMBCL)+2 more
Genmab
Testing effectiveness (Phase 2)UnknownNCT02267915
What this trial is testing

Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT

Who this might be right for
Mantle-cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 36
Early research (Phase 1)UnknownNCT02842138
What this trial is testing

Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma

Who this might be right for
B-cell Lymphoma
Peking University 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT03213652
What this trial is testing

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmMalignant Solid NeoplasmRecurrent Ependymoma+30 more
National Cancer Institute (NCI) 13
Testing effectiveness (Phase 2)Looking for participantsNCT03418038
What this trial is testing

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Who this might be right for
Clonal Cytopenia of Undetermined SignificanceHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+5 more
Mayo Clinic 80
Testing effectiveness (Phase 2)Study completedNCT03220035
What this trial is testing

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+20 more
National Cancer Institute (NCI) 4
Early research (Phase 1)Study completedNCT01535989
What this trial is testing

Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma

Who this might be right for
B-cell Lymphoma Refractory
Cristiana Sessa 25
Testing effectiveness (Phase 2)Study completedNCT00575068
What this trial is testing

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Biogen 42
Testing effectiveness (Phase 2)Ended earlyNCT02811679
What this trial is testing

Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin Lymphoma
Massachusetts General Hospital 13
Testing effectiveness (Phase 2)Looking for participantsNCT06834529
What this trial is testing

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

Who this might be right for
Relapsed or Refractory B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences 20
Early research (Phase 1)Study completedNCT01134341
What this trial is testing

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Who this might be right for
Cutaneous T-cell LymphomaMycosis FungoidesSezary Syndrome+1 more
Acrotech Biopharma Inc. 34
Early research (Phase 1)UnknownNCT04381741
What this trial is testing

CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine 24
Not applicableNo Longer AvailableNCT04705454
What this trial is testing

Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
ADC Therapeutics S.A.
Early research (Phase 1)Ended earlyNCT02706405
What this trial is testing

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma+3 more
Fred Hutchinson Cancer Center 30
Testing effectiveness (Phase 2)Looking for participantsNCT06486051
What this trial is testing

Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma

Who this might be right for
Large B-cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-cell Lymphoma (PMBCL)+1 more
Malaghan Institute of Medical Research 60
Next Page